國家衛生研究院 NHRI:Item 3990099045/9775
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 851406      在线人数 : 758
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9775


    题名: HQO-0601, an amide-containg 3, 4-dihydroquinolinone derivative, against human hematologic malignancies through inhibition of mammalian target of repamycin signaling pathway
    作者: Juang, SH;Yang, YC;Lee, CH;Lin, YC;Kuo, CC;Wang, TC
    贡献者: National Institute of Cancer Research
    摘要: Recently, the hydroxycoumarine skeleton of flavonols has been demonstrated to have a variety of biological activities including antioxidant properties and the ability to induce apoptosis. As a result, they have become the focus of intense studies aimed at developing novel compounds with pharmacological applications. Accordingly, we are interested in designing and synthesizing a series of amide-containing 3, 4-didhydroquinolinones (HQO) derivatives as novel hydroxycoumarine analogues and to evaluate their anti-cancer activities for further drug development. Of over sixty derivatives we tested, several amide substitute compounds showed excellent antiproliferative activity towards human nasopharyngeal carcinoma (NPC-TW01), lung carcinoma (H661), and leukemia (Jurkat) cells. Among them, HQO-0601 possesses great potency towards Jurkat cells with an IC50 of around 200 nM compared to the micromolar range of HQO-0601 needed for NPC-TW01 and H661 cells. In order to distinguish whether the antiproliferative effect of HQO-0601 is cell-line specific or tissue-specific, several human leukemia, solid tumors cells and peripheral blood mononuclear cells (PBMCs) were evaluated. Our results showed that leukemia cell lines are more sensitive to HQO-0601 treatment than solid tumor cell lines. Further examination also showed that HQO-0601 is not cytotoxic to PBMCs even at 50 \#956;M of HQO-0601, the highest concentration used. Further results indicated that HQO-0601 induces growth retardation at S-phase was accompanied by a marked decrease in the level of phosphorylation of CDK2 without affecting the CDK2 and cyclin A protein expression. Moreover, HQO-0601 treatment significantly alters the phosphorylation status of AKT and the mTOR effectors p70 S6 kinase. Taken together, our results strongly indicated that the HQO-0601 induced cell arrest of leukemia might involve in interrupting of the AKT/mTOR signaling pathway and merits further detailed studies.
    日期: 2009-05
    關聯: Cancer Research. 2009 May;69:Abstract number LB-51.
    Link to: http://cancerres.aacrjournals.org/content/69/9_Supplement/LB-51.short
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-5472&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000209702705033
    显示于类别:[郭靜娟] 會議論文/會議摘要
    [莊聲宏(1997-2004)] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000209702705033.pdf16KbAdobe PDF462检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈